Efficacy Study of Patient Preoperative Preps In-vivo

NCT ID: NCT04756154

Last Updated: 2024-10-01

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

154 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-07-06

Study Completion Date

2021-04-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the antimicrobial efficacy of an investigational CHG/IPA prep on skin flora of the inguinal regions of human subjects.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Non-inferiority of the investigational product to the FDA-approved active control for log10/cm2 recovery of skin flora relative to Treatment Day baseline log10/cm2 on the inguinal region at 10 minutes following application. Non-inferiority is based on a non-inferiority margin of 0.5 log10/cm2.

Superiority of the active products to the negative control for log10/cm2 recovery of skin flora relative to Treatment Day baseline log10/cm2 on the inguinal region at 10 minutes following application. A superiority margin of 1.2 log10/cm2 is used.

Number of observations for which the log10/cm2 recovery of skin flora on the inguinal region at 6 hours following application of the study products is higher than treatment day log10/cm2 baseline skin flora.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Surgical Skin Preparation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CHG/IPA Surgical skin preparation

Apply topically to the inguinal region for 2 minutes

Group Type EXPERIMENTAL

CHG/IPA Surgical skin preparation

Intervention Type DRUG

Apply topically to the inguinal region for 2 minutes

CHG/IPA Film-Forming Surgical skin preparation

Apply topically to the inguinal region for 2 minutes

Group Type ACTIVE_COMPARATOR

CHG/IPA Surgical skin preparation

Intervention Type DRUG

Apply topically to the inguinal region for 2 minutes

Normal saline

Apply topically to the inguinal region for 2 minutes

Group Type PLACEBO_COMPARATOR

Normal saline

Intervention Type DRUG

Apply topically to the inguinal region for 2 minutes

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CHG/IPA Surgical skin preparation

Apply topically to the inguinal region for 2 minutes

Intervention Type DRUG

Normal saline

Apply topically to the inguinal region for 2 minutes

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

2% CHG/70% IPA 0.9% sodium chloride

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects of any race
* Subjects in good health
* Minimum skin flora baseline requirements on inguinal region

Exclusion Criteria

* Any tattoos, scars, breaks in the skin, or any form of dermatitis, or other skin disorders (including acne) on the applicable test area
* Topical antimicrobial exposure within 14 days prior to screening and treatment days
* Use of systemic or topical antibiotics, steroid medications, or any other products known to affect the normal microbial flora of the skin within 14 days prior to screening and treatment days
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

3M

INDUSTRY

Sponsor Role collaborator

Solventum US LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Muhammad H Bashir, MD, CCRP

Role: PRINCIPAL_INVESTIGATOR

Microbac

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Microbac Laboratories, Inc

Sterling, Virginia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan: Combined Protocol and Statistical Analysis Plan

View Document

Document Type: Statistical Analysis Plan: Detailed Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EM-05-014624

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

AvenovaTM as a Sterile Skin Preparation Agent
NCT02990013 COMPLETED EARLY_PHASE1